High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy

Domenico Intiso, Valentina Simone, Filomena Di Rienzo, Andrea Iarossi, Luigi Pazienza, Andrea Santamato, Giuseppe Maruzzi, Mario Basciani

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Spasticity can be a severe disabling disorder requiring high-dose injections of botulinum toxin type A (BoNT-A). Efficacy and safety of high BoNT-A doses in reducing multi-level spasticity of subjects with brain injury and cerebral palsy were investigated. Pain and functional outcome were also assessed. METHOD: High doses (up to 840 IU) of incobotulinumtoxinA were injected in adult subjects with severe spasticity of the upper and lower limbs due to brain injury (BI) and cerebral palsy (CP). The Modified Ashworth Scale, Visual Analogue scale, Glasgow Outcome Scale, Franchay Arm Test (FAT) and Barthel Scale were employed to assess spasticity, pain and functional outcome at baseline, and 4 and 16 weeks after BoNT-A injection. Results: Twenty-two (12 M, 10 F; mean age 38.1 ± 13.7 years) subjects-16 subjects with BI and 6 with CP-were enrolled. Elbow, wrist, fingers and ankle muscles showed significant spasticity reduction after BoNT-A injections. The mean FAT score improved, but the benefit was not significant. Three (13.6%) subjects complained of mild adverse events. Conclusion: High-dose BoNT-A injections were effective and safe in reducing spasticity of BI and CP subjects. A significant reduction of the pain was also observed, but global functionality and arm dexterity were unchanged.

Original languageEnglish
Pages (from-to)515-522
Number of pages8
JournalNeuroRehabilitation
Volume34
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Type A Botulinum Toxins
Cerebral Palsy
Brain Injuries
Injections
Arm
Pain
Glasgow Outcome Scale
Elbow
Wrist
Visual Analog Scale
Ankle
Fingers
Lower Extremity
incobotulinumtoxinA
Safety
Muscles

Keywords

  • Botulinum toxin
  • brain injury
  • cerebral palsy
  • efficacy
  • high dose
  • spasticity

ASJC Scopus subject areas

  • Clinical Neurology
  • Rehabilitation
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy. / Intiso, Domenico; Simone, Valentina; Di Rienzo, Filomena; Iarossi, Andrea; Pazienza, Luigi; Santamato, Andrea; Maruzzi, Giuseppe; Basciani, Mario.

In: NeuroRehabilitation, Vol. 34, No. 3, 2014, p. 515-522.

Research output: Contribution to journalArticle

Intiso, Domenico ; Simone, Valentina ; Di Rienzo, Filomena ; Iarossi, Andrea ; Pazienza, Luigi ; Santamato, Andrea ; Maruzzi, Giuseppe ; Basciani, Mario. / High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy. In: NeuroRehabilitation. 2014 ; Vol. 34, No. 3. pp. 515-522.
@article{c0b8f364746247ec9bedc6e954beab70,
title = "High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy",
abstract = "Background: Spasticity can be a severe disabling disorder requiring high-dose injections of botulinum toxin type A (BoNT-A). Efficacy and safety of high BoNT-A doses in reducing multi-level spasticity of subjects with brain injury and cerebral palsy were investigated. Pain and functional outcome were also assessed. METHOD: High doses (up to 840 IU) of incobotulinumtoxinA were injected in adult subjects with severe spasticity of the upper and lower limbs due to brain injury (BI) and cerebral palsy (CP). The Modified Ashworth Scale, Visual Analogue scale, Glasgow Outcome Scale, Franchay Arm Test (FAT) and Barthel Scale were employed to assess spasticity, pain and functional outcome at baseline, and 4 and 16 weeks after BoNT-A injection. Results: Twenty-two (12 M, 10 F; mean age 38.1 ± 13.7 years) subjects-16 subjects with BI and 6 with CP-were enrolled. Elbow, wrist, fingers and ankle muscles showed significant spasticity reduction after BoNT-A injections. The mean FAT score improved, but the benefit was not significant. Three (13.6{\%}) subjects complained of mild adverse events. Conclusion: High-dose BoNT-A injections were effective and safe in reducing spasticity of BI and CP subjects. A significant reduction of the pain was also observed, but global functionality and arm dexterity were unchanged.",
keywords = "Botulinum toxin, brain injury, cerebral palsy, efficacy, high dose, spasticity",
author = "Domenico Intiso and Valentina Simone and {Di Rienzo}, Filomena and Andrea Iarossi and Luigi Pazienza and Andrea Santamato and Giuseppe Maruzzi and Mario Basciani",
year = "2014",
doi = "10.3233/NRE-141052",
language = "English",
volume = "34",
pages = "515--522",
journal = "NeuroRehabilitation",
issn = "1053-8135",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy

AU - Intiso, Domenico

AU - Simone, Valentina

AU - Di Rienzo, Filomena

AU - Iarossi, Andrea

AU - Pazienza, Luigi

AU - Santamato, Andrea

AU - Maruzzi, Giuseppe

AU - Basciani, Mario

PY - 2014

Y1 - 2014

N2 - Background: Spasticity can be a severe disabling disorder requiring high-dose injections of botulinum toxin type A (BoNT-A). Efficacy and safety of high BoNT-A doses in reducing multi-level spasticity of subjects with brain injury and cerebral palsy were investigated. Pain and functional outcome were also assessed. METHOD: High doses (up to 840 IU) of incobotulinumtoxinA were injected in adult subjects with severe spasticity of the upper and lower limbs due to brain injury (BI) and cerebral palsy (CP). The Modified Ashworth Scale, Visual Analogue scale, Glasgow Outcome Scale, Franchay Arm Test (FAT) and Barthel Scale were employed to assess spasticity, pain and functional outcome at baseline, and 4 and 16 weeks after BoNT-A injection. Results: Twenty-two (12 M, 10 F; mean age 38.1 ± 13.7 years) subjects-16 subjects with BI and 6 with CP-were enrolled. Elbow, wrist, fingers and ankle muscles showed significant spasticity reduction after BoNT-A injections. The mean FAT score improved, but the benefit was not significant. Three (13.6%) subjects complained of mild adverse events. Conclusion: High-dose BoNT-A injections were effective and safe in reducing spasticity of BI and CP subjects. A significant reduction of the pain was also observed, but global functionality and arm dexterity were unchanged.

AB - Background: Spasticity can be a severe disabling disorder requiring high-dose injections of botulinum toxin type A (BoNT-A). Efficacy and safety of high BoNT-A doses in reducing multi-level spasticity of subjects with brain injury and cerebral palsy were investigated. Pain and functional outcome were also assessed. METHOD: High doses (up to 840 IU) of incobotulinumtoxinA were injected in adult subjects with severe spasticity of the upper and lower limbs due to brain injury (BI) and cerebral palsy (CP). The Modified Ashworth Scale, Visual Analogue scale, Glasgow Outcome Scale, Franchay Arm Test (FAT) and Barthel Scale were employed to assess spasticity, pain and functional outcome at baseline, and 4 and 16 weeks after BoNT-A injection. Results: Twenty-two (12 M, 10 F; mean age 38.1 ± 13.7 years) subjects-16 subjects with BI and 6 with CP-were enrolled. Elbow, wrist, fingers and ankle muscles showed significant spasticity reduction after BoNT-A injections. The mean FAT score improved, but the benefit was not significant. Three (13.6%) subjects complained of mild adverse events. Conclusion: High-dose BoNT-A injections were effective and safe in reducing spasticity of BI and CP subjects. A significant reduction of the pain was also observed, but global functionality and arm dexterity were unchanged.

KW - Botulinum toxin

KW - brain injury

KW - cerebral palsy

KW - efficacy

KW - high dose

KW - spasticity

UR - http://www.scopus.com/inward/record.url?scp=84902278516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902278516&partnerID=8YFLogxK

U2 - 10.3233/NRE-141052

DO - 10.3233/NRE-141052

M3 - Article

VL - 34

SP - 515

EP - 522

JO - NeuroRehabilitation

JF - NeuroRehabilitation

SN - 1053-8135

IS - 3

ER -